Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The mdr-1 polymorphism G2677T/A in exon 21 correlates with the paclitaxel response in ovarian cancer and may be important for the function of P-glycoprotein and resistance to paclitaxel and provide useful information for individualized therapy.
|
16467099 |
2006 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We attempted to gain insight into the potential contribution of ovarian cancer genomic instability resulted from TP53 mutation to the aberrant expression of multidrug resistance gene MDR1.
|
28148293 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy.
|
18765553 |
2008 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These preclinical data suggest that a fiber-modified adenovirus vector under the control of the MDR1 promoter represents a promising treatment strategy for platinum-pretreated ovarian cancer as a single agent or in combination with conventional anticancer drugs.
|
22209976 |
2012 |
Malignant neoplasm of ovary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To fill this gap, we investigated the rate of gene amplification of the mdr1-gene in 63 recurrent ovarian carcinomas and we determined the resistance pattern of these cells using an ex vivo assay.
|
10656626 |
1999 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ovarian carcinoma cell line SKOV3 transducted with a human multidrug resistance gene (mdr1) served as the drug resistant model (SKOV3/mdr1).
|
11780384 |
2001 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The goal of this study is to evaluate the ability of HA-PEI/HA-PEG to deliver MDR1 siRNA and the efficacy of the combination of HA-PEI/HA-PEG/MDR1 siRNA with paclitaxel to suppress growth of ovarian cancer.
|
25687880 |
2015 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the effect of a MDR1 targeted fiber-modified CRAd against chemotherapy resistant ovarian cancer.
|
21741695 |
2011 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MDR1 gene is a direct target of the Wnt/β-catenin signaling pathway, which plays an important role in ovarian cancer.
|
26053275 |
2015 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
|
22842366 |
2012 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
The finding that the compound induced significantly more cell death in Pgp/MDR1 overexpressing OC cells compared to vincristine and paclitaxel warrants further development of the compound as a new therapy for OC patients with treatment refractory tumors and/or relapsing disease.
|
28496304 |
2017 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer.
|
25964202 |
2015 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data point at IMP-1 and MDR1 as indicators for response to therapy, and at IMP-1 as a novel therapeutic target for overcoming multidrug resistance of ovarian cancer.
|
21618519 |
2012 |
Malignant neoplasm of ovary
|
0.100 |
Biomarker
|
disease |
BEFREE |
Coinhibition of both Src and MDR-1 synergistically enhanced paclitaxel-induced cytotoxicity in paclitaxel-resistant ovarian cancer cell lines.
|
16288028 |
2005 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Co-expression of the MDR1 gene and HSP27 in human ovarian cancer.
|
9713493 |
1998 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although drug resistance is a major problem in treatment of ovarian cancer, resistance to the drugs most active against these tumors probably occurs through a mechanism other than expression of the MDR1 gene product.
|
1973872 |
1990 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
|
25515492 |
2015 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The drug concentrations applied referred to clinical relevant doses. mdr1 mRNA expression was significantly higher in specimens from recurrent ovarian cancer incubated in paclitaxel than in specimens from chemotherapy-naive ovarian cancer.
|
17001177 |
2006 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
|
11863219 |
2002 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The presence of even very low levels of MDR1 mRNA correlated with the lack of response to MDR regimens in these tumor types (P < .035 for ovarian carcinomas, P < .029 for SCLCs, and P < .0005 for both tumor types; Fisher's Exact Test).
|
1359152 |
1992 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A reduction in mdr-1 expression after 8-Cl-cAMP treatment was also observed in multidrug-resistant human ovarian cancer cell lines.
|
7543490 |
1995 |
Malignant neoplasm of ovary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results favor the expression of the MDR1 gene as one of the determinants involved in the acquired chemoresistance of ovarian cancers.
|
2766278 |
1989 |